Back to Search Start Over

Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect

Authors :
van de Kamp, J.M. (Jiddeke M.)
Pouwels, P.J.W. (Petra J.W.)
Aarsen, F.K. (Femke)
ten Hoopen, L.W. (Leontine W.)
Knol, D.L. (Dirk L.)
Klerk, J.B.C. (Johannes) de
Coo, I.F.M. (René) de
Huijmans, J.G.M. (Jan)
Jakobs, C. (Cornelis)
Knaap, M.S. (Marjo) van der
Salomons, G.S. (Gajja S.)
Mancini, G.M.S. (Grazia)
van de Kamp, J.M. (Jiddeke M.)
Pouwels, P.J.W. (Petra J.W.)
Aarsen, F.K. (Femke)
ten Hoopen, L.W. (Leontine W.)
Knol, D.L. (Dirk L.)
Klerk, J.B.C. (Johannes) de
Coo, I.F.M. (René) de
Huijmans, J.G.M. (Jan)
Jakobs, C. (Cornelis)
Knaap, M.S. (Marjo) van der
Salomons, G.S. (Gajja S.)
Mancini, G.M.S. (Grazia)
Publication Year :
2012

Abstract

The creatine transporter (CRTR) defect is a recently discovered cause of X-linked intellectual disability for which treatment options have been explored. Creatine monotherapy has not proved effective, and the effect of treatment with L-arginine is still controversial. Nine boys between 8 months and 10 years old with molecularly confirmed CRTR defect were followed with repeated1H-MRS and neuropsychological assessments during 4-6 years of combination treatment with creatine monohydrate, L-arginine, and glycine. Treatment did not lead to a significant increase in cerebral creatine content as observed with H1-MRS. After an initial improvement in locomotor and personal-social IQ subscales, no lasting clinical improvement was recorded. Additionally, we noticed an age-related decline in IQ subscales in boys affected with the CRTR defect.

Details

Database :
OAIster
Notes :
application/pdf, Journal of Inherited Metabolic Disease, pp. 1-9, English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn929972796
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1007.s10545-011-9345-1